Cationic Polypeptide Formulations for Local Antimicrobial Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing locally applied antimicrobials face challenges in achieving effective infection prevention and treatment while minimizing toxicities, particularly in pathophysiological settings such as open wounds and diseased skin, due to higher local and systemic sensitivities and absorption.
Innovation Solution
Development of cationic antimicrobial pharmaceutical compositions with specific molecular designs, formulations, and sterilization methods that enhance viscosity, retention time, and molecular integrity, reducing toxicities and improving tissue coverage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher doses of locally applied antimicrobials are used to achieve effectiveness in preventing and treating infections, then antimicrobial effectiveness is improved, but the risk of local and systemic toxicities increases
Solution Approach 1:
The patent modifies the chemical structure of cationic antimicrobial peptides by adjusting amino acid composition, charge density, and hydrophobicity parameters. These parameter changes enable the peptides to maintain antimicrobial effectiveness while reducing toxicity to mammalian cells, effectively resolving the contradiction between efficacy and safety.
Solution Approach 2:
The patent creates composite formulations by combining cationic antimicrobial peptides with specific excipients and carriers. These composite materials enhance the therapeutic index by improving selective toxicity against microbes while reducing adverse effects on host tissues, thereby achieving both effectiveness and safety.
2Reliability
If the concentration of cationic antimicrobial peptides is increased to improve antimicrobial activity, then antimicrobial performance is enhanced, but mammalian toxicity increases
Solution Approach 1:
The patent introduces amphipathic characteristics to the cationic peptides, creating regions of localized charge and hydrophobicity. This local quality differentiation allows the peptides to selectively interact with microbial membranes (which have different surface properties than mammalian cells) thereby enhancing antimicrobial activity at lower concentrations and reducing mammalian toxicity.
Solution Approach 2:
The patent systematically varies parameters such as net charge, amino acid sequence, and molecular weight to optimize the therapeutic window. By fine-tuning these parameters, the peptides achieve high antimicrobial potency at low concentrations, avoiding the toxicity associated with higher doses.
3Reliability
If locally applied antimicrobials are used in pathophysiological settings such as open wounds and diseased skin, then infection prevention and treatment capability is improved, but absorption and systemic distribution increase leading to higher sensitivities and toxicities
Solution Approach 1:
The patent employs segmented or block copolypeptide structures with distinct functional domains. One segment provides antimicrobial activity while another segment controls interaction with mammalian tissues and modulates absorption. This segmentation allows the peptide to exert local antimicrobial effects while minimizing systemic uptake and distant organ toxicity.
Solution Approach 2:
The patent uses specific excipients and formulation components as intermediaries that control the release and absorption profile of the cationic peptides. These intermediaries create a barrier that prevents excessive systemic absorption while maintaining effective local concentrations, thereby reducing the risk of distant organ toxicities.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions provide effective antimicrobial activity with low risk of local and systemic toxicities, enhancing safety and efficacy in various tissue sites and pathophysiological settings.
Implementation Method 1
A wide variety of cationic antimicrobials are known for their ability to bind to and disrupt bacterial membranes
Implementation Method 2
Development of cationic antimicrobial pharmaceutical compositions with specific molecular designs, formulations, and sterilization methods that enhance viscosity, retention time, and molecular integrity
Data Source
AI summary
Antimicrobial pharmaceutical compositions are formulated to allow local application in vivo of doses that provide antimicrobial effectiveness with low risk of local tissue toxicities and/or low risk of systemic/distant organ toxicities. In various embodiments the antimicrobial pharmaceutical compositions comprise antimicrobial synthetic cationic polypeptide(s) that are dispersed in an aqueous carrier and formulated to achieve a desired degree of polymer self-assembly and/or composition viscosity.